THE SHORT-TERM PERFORMANCE RESULTS OF PROSTATE ADENOCARCINOMA MULTIMODAL TREATMENT IN NOVOSIBIRSK REGION

The short-term performance criteria (PSA blood level and prostate volume) were analyzed concerning the complex (hormonal and radiation) treatment of 57 patients with prostate adenocarcinoma, stratified into three disease progression risk groups. Two treatment regimens were differed in the duration of neoadjuvant hormone therapy: 9 or 32 ± 13 months in combination with external beam radiation therapy with a total dose 76–80 Gy. Statistical analysis of the multimodal treatment efficiency criteria of patients with high risk of prostate adenocarcinoma showed the best result (significant decrease of PSA blood level) using a single 9-month course of hormone therapy and subsequent external beam radiation therapy. The prostate volume indicator in the applicable mode of radiation therapy has mixed dynamics, and requires further study as a multimodal treatment effectiveness criterion.

1. Donovan M.J., Costa J., Cordon-Cardo C. Personalized approach to prostate cancer prognosis. Arch Esp Urol 2011;64(8):783–91.

2. Kheirandish P., Chinegwundoh F. Ethnic differences in prostate cancer. Br J Cancer 2011;105(4):481–5.

3. Milecki P., Martenka P., Antczak A., Kwias Z. Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Mana Res 2010;(2):243–53.

4. Кунин И.С., Бобоев М.М., Куценко О.С. и др. Молекулярные маркеры метастазирования аденокарциномы предстательной железы. Онкоурология 2012;(4):44–8.

5. Suhovskih A.V., Mostovich L.A., Kunin I.S. et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncology 2013. 2013:680136. doi: 10.1155/2013/680136.

6. Карякин А.О., Матвеев В.Б., Свиридова Т.В. и др. Дистанционная лучевая терапия и длительная гормонотерапия у больных раком предстательной железы. Онкоурология 2011;(2);73–7.

7. Sasse A.D., Sasse E., Carvalho A.M., Macedo L.T. Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review. BMC Cancer 2012;12(54). doi: 10.1186/1471-2407-12-54.

8. Leitzmann M.F., Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol 2012;(4):1–11.

9. Pra A.D., Cury F.L., Souhami L. Radiation therapy and androgen deprivation in the management of high risk prostate cancer. Int Braz J Urol 2010;37(2):571–82.

10. Smith M.J., Akhtar N.H., Tagawa S.T. The сurrent role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically local -ized prostate cancer. Prostate Cancer 2012. Article ID 280278. doi:10.1155/2011/391576.